MH
Matthew Harrison Morgan Stanley Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
26
Innoviva
INVA
$1.29B
| $20.18 | $10 |
50%
downside
| Underweight |
3 Mar ‘23
2 years ago |
|
27
Fulcrum Therapeutics
FULC
$393M
| $7.24 | $8 |
11%
upside
| Equal-Weight |
28 Feb ‘23
2 years ago |
|
28
Galapagos
GLPG
$2.21B
| $32.67 | $44 |
35%
upside
| Equal-Weight |
27 Feb ‘23
2 years ago |
|
29
Sana Biotechnology
SANA
$762M
| $3.02 | $13 |
330%
upside
| Overweight |
24 Jan ‘23
2 years ago |
|
30
Lyell Immunopharma
LYEL
$250M
| $13.15 | $80 |
508%
upside
| Equal-Weight |
24 Jan ‘23
2 years ago |
|
31
Bolt Biotherapeutics
BOLT
$9.89M
| $5.03 | $60 |
1,093%
upside
| Equal-Weight |
24 Jan ‘23
2 years ago |
|
32
BioNTech
BNTX
$24.7B
| $102.09 | $216 |
112%
upside
| Equal-Weight |
24 Jan ‘23
2 years ago |
|
33
ADC Therapeutics
ADCT
$396M
| $3.32 | $5 |
51%
upside
| Equal-Weight |
24 Jan ‘23
2 years ago |
|
|
ADAG
34
Adagene
ADAG
$113M
| $2.50 | $5 |
100%
upside
| Overweight |
24 Jan ‘23
2 years ago |
|
35
AbbVie
ABBV
$371B
| $210.42 | $182 |
14%
downside
| Overweight |
6 Dec ‘22
2 years ago |
|
36
Kodiak Sciences
KOD
$517M
| $10.06 | $9 |
11%
downside
| Equal-Weight |
14 Nov ‘22
2 years ago |
|
37
Akero Therapeutics
AKRO
$3.57B
| $44.62 | $40 |
10%
downside
| Equal-Weight |
7 Nov ‘22
2 years ago |
|
38
Amgen
AMGN
$151B
| $279.97 | $282 |
1%
upside
| Overweight |
4 Nov ‘22
2 years ago |
|
39
Alnylam Pharmaceuticals
ALNY
$59.6B
| $482.13 | $210 |
56%
downside
| Equal-Weight |
28 Oct ‘22
2 years ago |
|
|
KLRS
40
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.8M
| $4.68 | $621 |
13,169%
upside
| Overweight |
9 Sep ‘22
3 years ago |
|
41
Pfizer
PFE
$140B
| $24.71 | $52 |
110%
upside
| Equal-Weight |
4 May ‘22
3 years ago |
|
42
Johnson & Johnson
JNJ
$429B
| $176.96 | $173 |
2%
downside
| Equal-Weight |
6 Apr ‘22
3 years ago |
|
43
Ultragenyx Pharmaceutical
RARE
$3.04B
| $31.50 | $120 |
281%
upside
| Overweight |
1 Feb ‘22
3 years ago |
|
44
Enliven Therapeutics
ELVN
$1.19B
| $19.72 | $16 |
19%
downside
| Equal-Weight |
6 Jan ‘22
3 years ago |
|
45
Merck
MRK
$210B
| $84.61 | $82 |
3%
downside
| Equal-Weight |
29 Nov ‘21
3 years ago |
|
46
Bristol-Myers Squibb
BMY
$95.1B
| $47.23 | $66 |
40%
upside
| Equal-Weight |
12 Oct ‘21
3 years ago |
|
47
Taysha Gene Therapies
TSHA
$884M
| $3.28 | $39 |
1,089%
upside
| Overweight |
18 Aug ‘21
4 years ago |
|
48
Royalty Pharma
RPRX
$15.5B
| $36.50 | $46 |
26%
upside
| Equal-Weight |
16 Aug ‘21
4 years ago |
|
49
Organon & Co
OGN
$2.72B
| $10.37 | $35 |
238%
upside
| Equal-Weight |
16 Aug ‘21
4 years ago |
|
50
Eli Lilly
LLY
$662B
| $750.61 | $275 |
63%
downside
| Overweight |
5 Aug ‘21
4 years ago |
|